Page 1,530«..1020..1,5291,5301,5311,532..1,5401,550..»

Good 4 You: Mental fitness for diabetes – WOAI

Posted: April 20, 2017 at 8:43 pm

by Delaine Mathieu, News 4 San Antonio

Good 4 You: Mental fitness for diabetes

There's a unique new therapy group in San Antonio designed to help people living with diabetes cope with the disease. It's called Mental Fitness for Diabetes. The goal of the program is to help treat mental side-effects that come along with diabetes. "I remember when I was diagnosed with diabetes," said Sarah Villegas. "March 31 for 2016. So, it's been a year."

The 71-year-old registered nurse was completely surprised when she was diagnosed with type two diabetes. "When the doctor came in and showed me my lab results," she explained. "I looked at the paper and I said, are you kidding me?"

Villegas lost seventeen pounds and got her condition under control. When she heard about this new mental fitness group, she was pleasantly surprised. "Never in my 49 years as a registered nurse -- to combine diabetes, a major chronic illness with a major mental health illness, which is chronic, and put them together -- that is an awesome concept," she said.

Valerie Moczgemba, with Alamo Wellness Group, will be running the sessions. "A lot of times, people who have been diagnosed with diabetes experience depression anxiety," she said. "There also may be anger or irritability. She said they'll be focusing on disease management and how mental health symptoms play into disease management.

Villegas says it's high time a treatment like this is made available for people with diabetes. "It cannot be ignored," she said. "We need to address their physical health issues as well as the mental issues. They both go hand-in-hand."

April 30th is the last day to register. If you're interested in signing up, go to alamowellnessgroup.com.

More here:
Good 4 You: Mental fitness for diabetes - WOAI

Posted in Diabetes | Comments Off on Good 4 You: Mental fitness for diabetes – WOAI

Researchers discover technique that could lead to diabetes cure – FOX 29

Posted: April 20, 2017 at 8:43 pm

by Zack Hedrick, Fox San Antonio

Researchers discover technique that could lead to diabetes cure

SAN ANTONIO Doctors in San Antonio have made a breakthrough discovery which could mean a potential cure for people with diabetes.

Tom Mathieu is a fanatical bike rider.

He believes he's pedaled more than 20,000 miles since he began riding in his early thirties.

He started riding because of a condition he was diagnosed with as a teenager.

Doctors told me it'd be a miracle that you see 60," said Mathieu.

Mathieu is a type 1 diabetic and his doctors tell him his body produces zero insulin.

He and his doctors believe his bike riding has helped keep his diabetes in check.

Well I'm 73 and I've had [diabetes] since I was 14," said Mathieu.

Researchers at UT Health San Antonio have discovered a strategy that could mean a cure.

It's a game changer, said Dr. Bruno Doiron. It change drastically the life of a patient that's diabetic."

Using a technique called gene transfer, doctors can alter other cells so they start to secrete insulin but only in response to sugar.

"Im using already what's naturally in your body," said Dr. Doiron.

The University Health System says diabetes is the 4th leading cause of death in Bexar County.

Mathieu calls the potential therapy revolutionary.

He says diabetes is a condition that requires discipline, but says this discovery would give a lot of freedom back to people dealing with diabetes.

People won't be burdened by what diabetes causes and then the cost of those causes, said Mathieu. I think it's miraculous."

Doctors say the therapy has cured diabetes in mice for one year without any side effects, which has never been done.

The goal is to conduct large-animal studies and human clinical trials in the next three to five years.

Facebook | Twitter |Email

View post:
Researchers discover technique that could lead to diabetes cure - FOX 29

Posted in Diabetes | Comments Off on Researchers discover technique that could lead to diabetes cure – FOX 29

Family members of diabetes patients plead for law to limit … – Las Vegas Review-Journal

Posted: April 20, 2017 at 8:43 pm

CARSON CITY Patients and family members of those who suffer from diabetes shared stories of struggle and heartbreak Wednesday and urged support for a bill to rein in the escalating costs of diabetes medication.

Bonnie Sedich knows the pain all too well. Four of her five children were diagnosed with juvenile diabetes. There was no family history. Two children died when in adulthood. Two others live with the disease.

One son, Jeffrey, was diagnosed at age 3. His body was found in a rural California region in 1981, a bottle of insulin by his side. He died at 19.

Another daughter, Elizabeth, was diagnosed when she was 8. She died in November at 51 of complications from the disease. Over the years, the cost of her drugs skyrocketed from about $10 a bottle to more than $300. Toward the end, she was paying more than $2,100 a month if she could afford it, Sedich said.

If you cant afford your diabetes medications then you just suffer and die, Sedich said.

She and others spoke at a press conference to urge support for Senate Bill 265. Sponsored by state Sen. Yvanna Cancela, D-Las Vegas, the bill would establish a list of insulin-related diabetic products to be treated as essential medications. It also would create a refund when insulin costs exceed the medical consumer price index.

The bill would require drug makers to divulge how prices are set, including the cost of medications, as well as amounts spent on marketing and research. It would set registration and reporting requirements on pharmaceutical sales representatives.

Diabetes is a serious disease that affects people for a lifetime, Cancela said. Medical costs are twice as high for people with diabetes.

Deadly and common

Diabetes is the eighth-leading cause of death in Nevada, where 12.4 percent of adults have the disease and 38 percent are pre-diabetic, she said.

Senate Majority Leader Aaron Ford, D-Las Vegas, is one of those who have been determined to be pre-diabetic. He said he received he diagnosis about a year ago.

Diabetes has become one of the largest public health crises in our time, and the medication to treat this disease must be affordable and accessible, he said. In this time of crisis, we have to come together.

Keyonna Lawrence said she was diagnosed as diabetic three years ago. A personal care assistant, she tries to control the disease through diet, and she stretches mediations when she can afford it by taking a half-dose.

My biggest fear is my 11-year-old son is going to wake up, say, Mom? and Moms as cold as ice, Lawrence said.

SB265 was granted an exemption and waiver from deadlines and remains pending in the Senate.

Contact Sandra Chereb at schereb@reviewjournal.com or 775-461-3821. Follow @SandraChereb on Twitter.

Sen. Yvanna Cancela, sponsor of Senate Bill 265, said diabetes care cost Nevadans about $2.4 billiion annually in medical costs.

Over the last 20 years, vials of the most commonn insulin products have gone from $17 to $138; and $21 to $255.

According to the American Diabetes Association, 281,355 people in Nevada, or 12.4 percent of the adult population, have diabetes. Another 787,000, or 38.5 percent of the adult population are pre-diabetic with blood glucose levels higher than normal.

The rest is here:
Family members of diabetes patients plead for law to limit ... - Las Vegas Review-Journal

Posted in Diabetes | Comments Off on Family members of diabetes patients plead for law to limit … – Las Vegas Review-Journal

Is Annual Eye Exam a Must for Type 1 Diabetes? – WebMD

Posted: April 20, 2017 at 8:43 pm

By Alan Mozes

HealthDay Reporter

WEDNESDAY, April 19, 2017 (HealthDay News) -- People with type 1 diabetes face the risk of developing a disease that can cause blindness, so treatment guidelines have long called for annual eye exams.

But new research suggests this one-size-fits-all advice is costly and ineffective, because people with a low risk may need less-frequent screenings while people at high risk may need to be seen more often.

Diabetic retinopathy can damage the light-sensitive tissue at the back of the eye and trigger full vision loss, the researchers explained. Screening can catch this disease before irreparable damage is done, but not every person with diabetes faces the same risk.

"For example, patients with no or minimal eye changes and good blood sugar levels might not need their next examination for another four years," said study author Dr. David Nathan.

"On the other hand, if the patient already has developing eye disease and their blood sugar control has not been in the recommended range, they might need a repeat examination in as soon as three months," he added.

Nathan is the director of the Diabetes Center and Clinical Research Center at Massachusetts General Hospital, in Boston.

Current guidelines suggest getting an annual eye screening within three to five years of a type 1 diabetes diagnosis. People with type 1 diabetes cannot produce any insulin.

To assess that advice, the investigators focused on type 1 diabetics (aged 13 to 39) who had enrolled in a large, national diabetes trial between 1983 and 1989.

The latest analysis involved 24,000 eye exams conducted over 30 years among roughly 1,400 people with type 1 diabetes.

Retinal photographs were taken every six months until 1993, and then -- in a follow-up study -- once every four years until 2012. The study participants' vision, advanced retinopathy status and general diabetes history were tracked for an average of nearly 29 years.

The researchers determined that those participants who had an average blood sugar level of 6 percent, but no signs of retinopathy, could forgo the annual screening in favor of just one exam every four years. Similar people with mild retinopathy should be screened once every three years, the team concluded.

By contrast, those with severe or moderate retinopathy would do well to get screened every three to six months, respectively, the study authors reported.

People with higher blood sugar levels (8 to 10 percent) might also need to be screened more often, the researchers cautioned.

On average, the new recommendations for people with type 1 diabetes would likely cut the need for eye exams in half over a two-decade period. That would translate into an overall savings of $1 billion, while ensuring that those facing the highest risk got more timely treatment, the researchers said.

The findings were published in the April 20 issue of the New England Journal of Medicine.

Nathan described the results as "definitive." However, he said the jury is still out as to "whether the individualized frequency of eye examinations will be implemented by physicians" and followed by people with type 1 diabetes.

"The risk is that physicians may find it easier to schedule an annual eye examination compared with the new individualized schedule, which may be more difficult for physicians and patients to remember," he acknowledged.

"However, most physicians and ophthalmology offices use computer programs -- including reminder programs -- for scheduling, so we think that this potential barrier should not be a substantial obstacle," Nathan added.

Courtney Cochran, senior manager of media relations for the American Diabetes Association (ADA), noted that the ADA issued updated guidelines for retinopathy screenings in February.

The new recommendations now state that people with type 1 diabetes should start annual screenings within five years of their diabetes diagnosis. But those who remain free of retinopathy for a year or two may "consider" the option of less-frequent exams.

However, the ADA also said that if and when "any level" of retinopathy is detected, annual screenings are a must, while those with progressing retinopathy will require even more frequent screenings.

Dr. Jamie Rosenberg, who wrote an editorial that accompanied the study, suggested the new recommendations reflect "a trend toward reducing unnecessary screening for eye diseases."

"The upside to this new screening protocol would be significant money saved for the health care system, in addition to time saved for both patients and doctors," said Rosenberg, who is an associate professor of clinical ophthalmology and visual sciences at the Albert Einstein College of Medicine, in New York City.

Individualized schedules will make tracking patients more difficult, Rosenberg agreed. But, "this new screening protocol has great potential if adherence to the examination schedule could be assured."

WebMD News from HealthDay

SOURCES: David Nathan, M.D., director, Diabetes Center and Clinical Research Center, Massachusetts General Hospital, and professor, medicine, Harvard Medical School, Boston; Jamie Rosenberg, M.D., associate professor, clinical ophthalmology & visual sciences, and associate professor, clinical pediatrics, Albert Einstein College of Medicine, and attending physician, Montefiore Health System, New York City; Courtney Cochran, senior manager, media relations, American Diabetes Association; April 20, 2017, New England Journal of Medicine

Visit link:
Is Annual Eye Exam a Must for Type 1 Diabetes? - WebMD

Posted in Diabetes | Comments Off on Is Annual Eye Exam a Must for Type 1 Diabetes? – WebMD

Young minds meet new technology at STEM-focused after-school program – USC News

Posted: April 19, 2017 at 6:44 pm

La Bella Saunders gasped as she steppedtoward the giant fuchsia nucleus floating in front of her. She giggled as she reached out toward two oblong, orange mitochondria and an electric blue ball of protein, then lowered her head to look through a small pore one of dozens of openings in the nucleus to spy the DNAinside.

Saunders, a fifth-grader at Foshay Learning Center near USCs University Park Campus, was exploring human biology using a virtual-reality headset that put her inside a cell.

The experience was part of a Young Scientists Program (YSP) after-school workshop on emerging technologies, held March 22 at the school. YSP is a STEM (science, technology, engineering and math) learning initiative hosted through theJoint Educational Project (JEP) of the USC Dornsife College of Letters, Arts and Sciences.

In addition to exploring virtual and augmented reality, the 25 fourth- and fifth-grade participants experienced 3-D printing and drones many for the first time.

We chose these three fields because they are key elements in todays newly emerging technologies, said JEP STEM Program Manager Dieuwertje DJ Kast, who organized the workshop.

I want to show the YSP students what is possible and introduce them to potential careers that could spring from what theyre learning about today, she said. I also want to help level the playing field by giving them the opportunity to get exposure to this technology now, while theyre young.

Students spent 20 minutes at differentstations learning aboutthe three emerging technologies. YSP teaching assistants were on hand to ensure the youngsters had fun while also understanding the underlying science.

At the 3-D printing station, students designed objects in a virtual space using the 3D Slash computer program. This gave them firsthand experience of how architects and engineers, who work with 3-D concepts, think and design. Thanks to local 3-D printing company Deezmakers, students were able to observe printers in action. They watchedintentlyas their teachers and YSP staff were scanned by the Deezmaker selfie setup, which printed out tiny 3-D models.

At the drone station, students sawprofessional drone pilot Roee Fung fly a selection of four quadcopter drones. They grinned for the camera as a tiny, remote control aircraft snapped aerial drone selfies of them as it hovered overhead.

After watching the aerial drones, 10-year-old Maurice Stepter focused on building a fan-driven drone car of his own using a plastic lunch box, wheels, a propeller and a tiny battery-driven motor. It was the fourth-graders first time attending a YSP event.

When I got here it was like, Whoa, this is cool, and that made me want to stay.

Maurice Stepter

Some teachers were encouraging me to come along today so I did, and when I got here it was like, Whoa, this is cool, and that made me want to stay, he said.

Four stations were dedicated to VRand augmented reality, including the Into the Cell experience, a VR project built by Smart Sparrow Inc. and presented by Jessica Swann and Joe Tamer from Arizona State Universitys Center for Education Through eXploration. Students also got to experience a virtual safari, a roller coaster ride and a dive to the depths of the ocean, thanks to WeLens, which donated 50 cardboard VR headsets for students to take home.

Students learned about erosion by playing with the Deezmakers augmented reality sandbox, which changes the color of sand according to its depth. That allowed YSP staff to explain topographical maps by giving students hands-on experience with creating their own landscapes.

At another station, YSP teaching assistant Michelle Huber, a senior majoring in environmental studies at USC Dornsife, was helping students create holograms by cutting and folding transparencies into a trapezoidal shape and placing them on top of a smartphone inside a black box. As the phone played a video of a blue jellyfish, the images were reflected in the trapezoid, creating a hologram.

Working with YSP helped Huber realize that she wants to pursue a career in teaching. I want to go into education because I have really enjoyed programs like this one that involve teaching young kids, she said.

Saunders was impressed with the YSP workshop.I learned all about cells and how drones can help save people by showing firefighters the places they need to put out fires, she said.

Kast emphasized the importance of YSP workshops in introducing students to STEM and helping them advance on the path that will allow them to turn their career dreams into reality.

These workshops are extremely valuable because they really show students whats possible, she said, whether that involves careers, experiences or opportunities.

Jasmine Tigolo, Saunders teacher at Foshay, agreed, saying she was delighted to be able to offer YSP to her students.

This is the sort of up-to-date technology they need to know in order to be able to compete in the outside world, she said, so exposing them to something while theyre this young is phenomenal.

More stories about: Community Outreach, Joint Educational Project, Virtual Reality

Experts and peers in their respective fields agree: These Trojans are changing the world.

With the help of USC undergrads, fourth- and fifth-graders take part in a skills-shaping event hosted by the Joint Educational Project.

Students learn to write code, design games and control robots at a computer science workshop.

The Joint Educational Project curriculum brings in a weatherman to talk with youngsters about meteorology.

See the rest here:
Young minds meet new technology at STEM-focused after-school program - USC News

Posted in Arizona Stem Cells | Comments Off on Young minds meet new technology at STEM-focused after-school program – USC News

3D-printed Patch Can Help Mend a ‘Broken’ Heart – Technology Networks

Posted: April 19, 2017 at 6:43 pm


Technology Networks
3D-printed Patch Can Help Mend a 'Broken' Heart
Technology Networks
In this study, researchers from the University of Minnesota-Twin Cities, University of Wisconsin-Madison, and University of Alabama-Birmingham used laser-based 3D-bioprinting techniques to incorporate stem cells derived from adult human heart cells on ...

See the article here:
3D-printed Patch Can Help Mend a 'Broken' Heart - Technology Networks

Posted in Alabama Stem Cells | Comments Off on 3D-printed Patch Can Help Mend a ‘Broken’ Heart – Technology Networks

Plandai Biotechnology Sets Aggressive Agenda for 2017 – Yahoo Finance

Posted: April 19, 2017 at 6:42 pm

NEW YORK, NY--(Marketwired - April 19, 2017) - Planda Biotechnology (PLPL) recently presented investors with its outlook for 2017 and a number of milestones that the company plans to accomplish in 2017. Planda's plans are certainly aggressive and representative of the new Chief Operating Officer (COO) -- someone we feel is ideally suited to move the company forward. It didn't take long at all for the new COO, Callum Cottrell-Duffield, to put his stamp on the company's future.

Three weeks ago Planda named Callum Cottrell-Duffield as its new COO, a role that will have him running the day-to-day operations of the company. In the time since being named COO, he has put together a plan to not only get Planda back on track, but to also move it aggressively into the future. With Planda shifting from purely a research and development biotechnology company to a company that is more focused on operations and sales, Callum Cottrell-Duffield is the ideal person to run Planda's day-to-day activity.

After all, he has been there from the beginning where he helped to prepare the company's 8,000-acre tea estate to grow, harvest and produce Planda's signature product, the highly bioavailable Phytofare Catechin Complex. Last year when that signature product was available for mass production and ready to market on a much broader scale, it was Callum Cottrell-Duffield who led the company's sales and marketing team. He has traveled throughout Africa, the United States, Europe, Asia and South America to tell the Planda story, and he has become the face of the company to the industry and to the large buyers who are either current clients or interested in developing a relationship with Planda worldwide.

In the company's latest news release, the COO highlighted several areas where he expects to see improvement and areas where Planda can realize growth. Among those items, Callum Cottrell-Duffield said that he (i) has placed getting the company "current" with its SEC filings at the top of his agenda, (ii) expects to increase production and to continue growing sales with Planda's existing customers as well as gaining traction in the market, which should lead to the addition of new customers all in an effort to make Planda cash flow positive and profitable by the end of 2017, (iii) recently signed a financing agreement that will provide the necessary capital to see the company through until it becomes cash flow positive.

With the appointment of Callum Cottrell-Duffield to COO, the company's CEO, Roger Baylis-Duffield, can now focus his efforts as a scientist on spearheading the company's clinical trials and developing new products for Planda to market. In the company's research and development efforts, the CEO will be busy with a number of major studies this year.

According to the COO, Planda's work in the clinic will include:

Additionally, Planda has granted a research license to Protext Mobility to develop pharmaceutical applications involving Phytofare. Protext will be conducting a human study using Phytofare to regulate glucose levels in Type 2 diabetics as well as, taking over the research to establish a platform for producing non-psychoactive Cannabis. Planda states that the plan for Protext is to produce a Phytofare complex containing bioavailable cannabinoids, cannabinoid acids, and polyphenols that will be formulated into an oral delivery system.

Needless to say, with success in these studies, these are all areas where Planda could develop much-needed products that could, in turn, drastically improve the company's bottom line. For a full look into the COO's agenda for 2017, read Planda's latest news release here:

http://finance.yahoo.com/news/plandai-biotechnology-chief-operating-officer-162043100.html

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

Read More

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: http://www.stockmarketmediagroup.com.

Read more from the original source:
Plandai Biotechnology Sets Aggressive Agenda for 2017 - Yahoo Finance

Posted in Biotechnology | Comments Off on Plandai Biotechnology Sets Aggressive Agenda for 2017 – Yahoo Finance

Puma Biotechnology Inc (PBYI) Plunges 6.94% on April 18 – Equities.com

Posted: April 19, 2017 at 6:42 pm

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a rough trading day for Tuesday April 18 as shares tumbled 6.94%, or a loss of $-2.75 per share, to close at $36.85. After opening the day at $39.90, shares of Puma Biotechnology Inc traded as high as $40.55 and as low as $35.85. Volume was 2.06 million shares over 12,951 trades, against an average daily volume of 910,555 shares and a total float of 36.95 million.

As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.36 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $37.71 and 200-day SMA is $42.98.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Follow this link:
Puma Biotechnology Inc (PBYI) Plunges 6.94% on April 18 - Equities.com

Posted in Biotechnology | Comments Off on Puma Biotechnology Inc (PBYI) Plunges 6.94% on April 18 – Equities.com

Does the US have the biotechnology and other tools to deal with the next wave of diseases? – Genetic Literacy Project

Posted: April 19, 2017 at 6:42 pm

[Editors note:Tom Frieden served seven and a half years as director of the U.S. Centers for Disease Control and Prevention. He talks about health challenges facing the nation, as well as memorable moments from his tenure.]

What immediate health issues are facing the Trump administration?

Tom Frieden: Zika is not over. It is likely to spread in Latin America and the Caribbean for months and years to come, and we still dont fully understand the range of birth defects it causes. Antibiotic resistance in the U.S. is something that threatens to undermine modern medicineAnd we are always concerned about an influenza epidemic.

How prepared is the CDC to deal with these problems?

Its a big problem that when there is an emerging threat, we are not able to surge or work as rapidly as we should, as a result of a lack of additional funding and legislative authority. When there is an earthquake, the Federal Emergency Management Agency doesnt have to go to Congress and say, Will you give us money for this? But the CDC doesA blind spot anywhere puts any of us at risk.

What do you consider unfinished business or a regret?

I hoped that we would be over the finish line on polio [eradication] by now[But] we have further to go.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Is the U.S. Ready for Future Disease Threats?

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Originally posted here:
Does the US have the biotechnology and other tools to deal with the next wave of diseases? - Genetic Literacy Project

Posted in Biotechnology | Comments Off on Does the US have the biotechnology and other tools to deal with the next wave of diseases? – Genetic Literacy Project

Reminder: San Diego stem cell meeting open to the public tomorrow – The San Diego Union-Tribune

Posted: April 19, 2017 at 6:42 pm

Interested in learning about stem cell science and medicine and what it means to you? A public meeting will be held Thursday from noon to 1 p.m. at the Sanford Consortium for Regenerative Medicine in La Jolla.

Heres more details from my earlier story.

Not only will researchers and a patient advocate with Parkinsons disease discuss the state of stem cell treatments, the public will be able to ask questions.

The Sanford Consortium building is located across the street from the Salk Institute. For those seeking a bite to eat before or after the event, the building also hosts a bistro, the Bella Vista Social Club and Cafe.

The video with this story shows Sandra Dillon describing how she regained stamina and energy after an experimental treatment that blocked cancer stem cells. While not a cure, the treatment reversed what appeared to be an inevitable downward progression.

Dillions doctor, physician-researcher Catriona Jamieson, will be one of the speakers at tomorrows event.

Ill be on site at the event, and will have a report(s) up tomorrow afternoon.

bradley.fikes@sduniontribune.com

(619) 293-1020

More:
Reminder: San Diego stem cell meeting open to the public tomorrow - The San Diego Union-Tribune

Posted in Cell Medicine | Comments Off on Reminder: San Diego stem cell meeting open to the public tomorrow – The San Diego Union-Tribune

Page 1,530«..1020..1,5291,5301,5311,532..1,5401,550..»